Key facts
- Cresilon’s last known valuation is $340.0M (Apr 2024).
- It has raised $159.5M across 8 recorded rounds; the latest was Early Stage VC ($29.0M) in Apr 2026.
- Notable investors include Dorm Room Fund, First Round Capital, Catalio Capital Management, NYU Summer Launchpad, Hammerstone Capital — 20 tracked in total.
- Cresilon has filed 8 Form Ds with the SEC since 2018, most recently Jun 2026 ($29.0M sold to 217 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Cresilon
Funding rounds
8 roundsAbout Cresilon
Developer of hemostatic products designed to support the natural clotting and promote wound healing. The company's products are plant-based polymers that rapidly adhere to the wound site and stop bleeding by creating a mechanical barrier, enabling medical practitioners to control external traumatic bleeding, improve wound care, and advance medical treatment.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2012
- Employees
- 88
- Website
- cresilon.com/
- Ownership
- Privately Held (backing)
Cresilon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cresilon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cresilon in its N-PORT filings yet. We sweep new filings monthly.